Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Outlines Next Steps In Regulatory Science

This article was originally published in The Gray Sheet

Executive Summary

FDA plans to invest in eight priority areas for regulatory science, including better tools for reviewing innovative technologies and new manufacturing approaches, according to a strategic plan released Aug. 17.
Advertisement

Related Content

New Subcommittee To Look Afresh At FDA Regulatory Science Needs
FDA Develops Scientific Integrity Guide For Staff
Regulatory News In Brief
Regulatory News In Brief
Could Regulatory Science Raise The Bar For Industry?
Could Regulatory Science Raise The Bar For Industry?
Regulatory News In Brief
CDRH's Innovation Pathway: A Quicker Route For Breakthrough Devices?
Regulatory Science Plan Would Create New Office In FDA
Regulatory Science Plan Would Create New Office In FDA

Topics

Advertisement
UsernamePublicRestriction

Register

MT030458

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel